Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...

Having raised more than $1 million toward cancer research over the past nine years, the tournament is on the road to raising ...

Cancer cells have special adaptation mechanisms that allow them to proliferate despite changes in their genetic makeup.

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...

The human body is teeming with trillions of symbiotic microorganisms, profoundly impacting our well-being. Within the gut, ...

There could be new hope on for kidney cancer patients. Researchers announced early results of an anti-tumor vaccine for patients with stage 3 or 4 kidney cancer, who face high recurrence risk.

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...

One of the pillars of modern medicine is the life-saving drugs that pharmaceutical companies spend years developing to cure ...

Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

Five years since it launched, advances powered by the National Drug Discovery Centre are helping transform medical research in Australia and fast-tracking development of new home-grown treatments.